IMO, they massively overestimated the current technology integrated with ADAPT, management should have seen this a year ago instead of pouring more CR money into the commercialisation and just did a similar deal like they did with LMAT who already had decade of market presence.....new product currently in clinical trial, whether this will be more successful then the current product is why investor are buying, MC is currently minuscule compared to the potential revenue market this product will be entering.
Ann: Unusual Trading Patterns, page-155
-
- There are more pages in this discussion • 60 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.31 |
Change
-0.240(1.29%) |
Mkt cap ! $351.9M | |||
| Open | High | Low | Value | Volume |
| $18.80 | $19.15 | $18.20 | $159.7K | 8.611K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 73 | $18.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.33 | 90 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |